CEO Message
CEO Message
Hello and welcome! I’m James Park, Chief Executive Officer of LOTTE BIOLOGICS. In 2022, we launched into the biopharmaceutical CDMO world with a clear vision: to help create a healthier tomorrow with our commitment to advancing human health. As we grow toward becoming a top-tier global CDMO, we stand by four fundamental pillars: Collaboration, Excellence, Accountability, and Transparent Communication. Collaboration – Powerful Partnerships Across BoundariesOur dual-site approach offers the best of both worlds. With operational facilities in Syracuse, USA, and a soon-to-be-completed site in Songdo, South Korea, we’re able to support your smaller-scale projects to large-scale commercial production. Excellence – World-Class Molecule-to-Medicine Platform
From early development through clinical trials and commercial manufacturing, our molecule-to-medicine services comprehensively have you covered. Our Syracuse Bio Campus has earned over 62 manufacturing approvals from global authorities such as the FDA, EMA, and PMDA. In 2025, we expanded our ADC capabilities, making it a true one-stop ADC conjugation hub in North America, spanning monoclonal antibody production through final conjugation, all under one roof. Meanwhile, our Songdo Bio Campus targets a 120,000L commercial production capacity by 2027, and it’s on track to become a major global biomanufacturing hub by 2034. Accountability – Protecting Patient Lives Through Quality-First Mindset
In everything we do, quality remains our foremost priority. The medications we produce directly impact patients' lives, which is why every team member embraces our quality-first mindset without compromise. Transparent Communication - Building Partnerships through Trust
Long-lasting partnerships thrive on honest, open dialogue. By staying transparent, we make sure our clients’ needs and expectations are always front and center. Contributing to healthier lives worldwide is our top mission. LOTTE BIOLOGICS will continue to lead in the global CDMO market, dedicated to ongoing innovation and elevated quality as we move forward and grow together. Sincerely, James Park Chief Executive Officer, LOTTE BIOLOGICS